An Open-Label Randomized Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

Brief description of study

If you have been diagnosed with recurrent or metastatic, platinum- refractory cervical cancer, you may qualify for a clinical trial comparing how long you survive using an investigational drug, REGN2810 or an investigator's choice (IC) chemotherapy regimen. The goal of this phase III trial is to compare overall survival in patients utilizing REGN2810 vs. IC chemotherapy. The trial will also look at immediate and long-term side effects, as well as outcomes such as quality of life in both treatment groups.

Clinical Study Identifier: s17-00406 Identifier: NCT03257267

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.